

Bhuvana A Setty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5293617/publications.pdf>

Version: 2024-02-01

29
papers

429
citations

840776

11
h-index

752698

20
g-index

31
all docs

31
docs citations

31
times ranked

722
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp><i>EGFR</i></scp> internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors. <i>Genes Chromosomes and Cancer</i> , 2023, 62, 17-26.	2.8	3
2	Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. <i>British Journal of Radiology</i> , 2022, 95, 20211088.	2.2	1
3	Syringocystadenocarcinoma Papilliferum in a Fifteen-Year-Old Girl: A Case Report and Review of the Literature. <i>Case Reports in Dermatological Medicine</i> , 2022, 2022, 1-5.	0.3	1
4	Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29548.	1.5	3
5	Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma: A report from the National Pediatric Cancer Foundation.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10042-10042.	1.6	0
6	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. <i>European Journal of Cancer</i> , 2022, 173, 71-90.	2.8	9
7	Bilateral Lung Metastases From a Phalangeal Giant Cell Tumor of Bone. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 51-55.	1.0	1
8	Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS11577-TPS11577.	1.6	1
9	Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11514-11514.	1.6	7
10	Case 3: Abdominal Distention, Shock, and Neonatal Encephalopathy. <i>NeoReviews</i> , 2021, 22, e406-e408.	0.8	0
11	Discovery of clinically relevant fusions in pediatric cancer. <i>BMC Genomics</i> , 2021, 22, 872.	2.8	13
12	Infantile fibrosarcoma-like tumor driven by novel <i>RBPMS-MET</i> fusion consolidated with cabozantinib. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005645.	1.2	17
13	Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28370.	1.5	15
14	The genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss. <i>PLoS Genetics</i> , 2020, 16, e1008642.	3.5	18
15	A pediatric and young adult phase I dose escalation study of BXQ-350 for solid and central nervous system tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2541-2541.	1.6	2
16	A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS11567-TPS11567.	1.6	4
17	Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease. <i>Oncotarget</i> , 2020, 11, 510-522.	1.8	26
18	First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. <i>Molecular Therapy</i> , 2019, 27, 1930-1938.	8.2	41

#	ARTICLE	IF	CITATIONS
19	Off label targeted therapy use in adolescents and young adults with sarcoma.. Journal of Clinical Oncology, 2019, 37, e21504-e21504.	1.6	0
20	Vincristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. Pediatric Blood and Cancer, 2018, 65, e26728.	1.5	30
21	A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin. Pediatric Blood and Cancer, 2018, 65, e27224.	1.5	24
22	Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatric Blood and Cancer, 2017, 64, e26473.	1.5	14
23	Hypoxia-induced proliferation of HeLa cells depends on epidermal growth factor receptor-mediated arginase II induction. Physiological Reports, 2017, 5, e13175.	1.7	9
24	Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases. Case Reports in Oncology, 2016, 9, 447-453.	0.7	0
25	Hypoxic Proliferation of Osteosarcoma Cells Depends on Arginase II. Cellular Physiology and Biochemistry, 2016, 39, 802-813.	1.6	11
26	A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, doxorubicin, and PEG-asparaginase (VPLD).. Journal of Clinical Oncology, 2016, 34, 10530-10530.	1.6	0
27	Pediatric venous thromboembolism in the United States: A tertiary care complication of chronic diseases. Pediatric Blood and Cancer, 2012, 59, 258-264.	1.5	155
28	Heterozygous M1V variant of ELA2 gene mutation associated with CSF refractory severe congenital neutropenia. Pediatric Blood and Cancer, 2011, 57, 514-515.	1.5	8
29	Rare Pediatric Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports, 2010, 5, 163-168.	2.3	16